Atlas One · Host Biology · Scale 07 — System

Giant Cell Arteritis

Giant cell arteritis (GCA) is the most common primary vasculitis in adults >50; granulomatous inflammation of temporal arteries and aortic branches; IL-6 and IL-1β drive pathogenesis. Tocilizumab (anti-IL-6R; GiACTA; FDA May 2017) is the first approved steroid-sparing therapy.

Also known as: GCA, giant cell arteritis, temporal arteritis, cranial arteritis, Horton disease, polymyalgia rheumatica

Scale 07 — SystemScale
draftStatus
2026-06-07Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
giant-cell-arteritis

Giant Cell Arteritis

Giant cell arteritis (GCA) is the most common primary vasculitis in adults >50; granulomatous inflammation of temporal arteries and aortic branches; IL-6 and IL-1β drive pathogenesis. Tocilizumab (anti-IL-6R; GiACTA; FDA May 2017) is the first approved steroid-sparing therapy.